Peter J Allen, Mithat Gönen, Murray F Brennan, Adjoa A Bucknor, Lindsay M Robinson, Marisa M Pappas, Kate E Carlucci, Michael I D'Angelica, Ronald P DeMatteo, T Peter Kingham, Yuman Fong, William R Jarnagin
BACKGROUND: Postoperative pancreatic fistula is a major contributor to complications and death associated with pancreatic resection. Pasireotide, a somatostatin analogue that has a longer half-life than octreotide and a broader binding profile, decreases pancreatic exocrine secretions and may prevent postoperative pancreatic fistula. METHODS: We conducted a single-center, randomized, double-blind trial of perioperative subcutaneous pasireotide in patients undergoing either pancreaticoduodenectomy or distal pancreatectomy...
May 22, 2014: New England Journal of Medicine